loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Bremelanotide

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Bremelanotide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 322,960Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Palatin Doses First Patient In Bremelanotide-Tirzepatide Obesity Trial
    Palatin Doses First Patient In Bremelanotide-Tirzepatide Obesity Trial

    23 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-dosed-in-phase-2-clinical-study-of-palatins-bremelanotide-co-administered-with-tirzepatide-glp-1-for-the-treatment-of-obesity-302228157.html

    PR NEWSWIRE
    23 Aug 2024
    Share Share
    Palatin Begins Phase 2 Study Of Bremelanotide With PDE5i For ED Treatment
    Palatin Begins Phase 2 Study Of Bremelanotide With PDE5i For ED Treatment

    20 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-announces-the-initiation-of-a-phase-2-clinical-study-of-bremelanotide-co-administered-with-a-pde5i-for-the-treatment-of-erectile-dysfunction-ed-302177672.html

    PR NEWSWIRE
    20 Jun 2024
    Share Share
    Palatin Initiates Phase 2 Study Of Bremelanotide For Obesity
    Palatin Initiates Phase 2 Study Of Bremelanotide For Obesity

    12 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-initiates-phase-2-clinical-study-of-bremelanotide-for-the-treatment-of-obesity-302170728.html

    PR NEWSWIRE
    12 Jun 2024
    Share Share
    Cosette Pharmaceuticals Acquires Vyleesi from Palatin Technologies Inc.
    Cosette Pharmaceuticals Acquires Vyleesi from Palatin Technologies Inc.

    03 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240103181501/en

    BUSINESSWIRE
    03 Jan 2024
    Share Share
    Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
    Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

    02 Jan 2024

    // INDIAN PHARMA POST

    https://www.indianpharmapost.com/news/palatin-completes-sale-of-vyleesi-to-cosette-pharmaceuticals-for-up-to-171-mn-15086

    INDIAN PHARMA POST
    02 Jan 2024
    Share Share
    Palatin Completes Sale of Vyleesi® to Cosette Pharma for up to $171 Million
    Palatin Completes Sale of Vyleesi® to Cosette Pharma for up to $171 Million

    20 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-completes-sale-of-vyleesi-to-cosette-pharmaceuticals-for-up-to-171-million-302020026.html

    PR NEWSWIRE
    20 Dec 2023
    Share Share